Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial

Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy

(2020) Thomas Menter et al.   BRITISH JOURNAL OF HAEMATOLOGY

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

(2019) Emanuele Zucca et al.   BLOOD

Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment

(2019) Isacco Ferrarini et al.   LEUKEMIA & LYMPHOMA

T follicular helper cells: a potential therapeutic target in follicular lymphoma

(2017) Jordi Ochando et al.   Oncotarget

Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma

(2015) Elisa Ferretti et al.   OncoImmunology

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

(2011) P. Jain et al.   HAEMATOLOGICA

IL-17 Activates the Canonical NF-κB Signaling Pathway in Autoimmune B Cells of BXD2 Mice To Upregulate the Expression of Regulators of G-Protein Signaling 16

(2010) Shutao Xie et al.   JOURNAL OF IMMUNOLOGY

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

(2009) Irina Idler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Differential Roles of Interleukin-17A and -17F in Host Defense against Mucoepithelial Bacterial Infection and Allergic Responses

(2009) Harumichi Ishigame et al.   IMMUNITY

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma

(2008) A. Tzankov et al.   HAEMATOLOGICA